Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Molenbeek-Saint-Jean – page 95

2 121 clinical trials in Molenbeek-Saint-Jean, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Molenbeek-Saint-Jean at a glance
2 121
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 121 trials in Molenbeek-Saint-Jean

Open in trial search

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

COVID-19

Not recruiting

A study of the effects of nirmatrelvir, ritonavir, and rosuvastatin in healthy adult participants

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Nirmatrelvir
  • Sponsor:Pfizer Inc.

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Safety, Tolerability and Pharmacokinetics of MK-7480 and Diltiazem Hydrochloride in Healthy Adult Male Participants for Non‑alcoholic Steatohepatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:MK-7480
  • Sponsor:Merck Sharp & Dohme LLC

Evaluation of safety and efficacy of 19CP02 combined with cyclophosphamide and fludarabine phosphate in adults with treatment‑refractory active systemic lupus erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Lakefront Biotherapeutics

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Malaria

Not recruiting

Multiple Ascending Dose Safety, Tolerability and Pharmacokinetics of MK-7602 in Healthy Volunteers for Malaria

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:MK-7602
  • Sponsor:Merck Sharp & Dohme LLC

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

Iron overload

Not recruiting

Safety and Tolerability of REGN7999 in Healthy Adult Participants

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:REGN7999
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm malignant

Not recruiting

Phase 1 safety and dose-finding study of NG-350A plus pembrolizumab in patients with metastatic cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NG-350A
  • Sponsor:Akamis Bio Limited

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Molenbeek-Saint-Jean

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research explores alternative treatment approaches for managing functional dyspepsia and related gastrointestinal conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

Comparing effectiveness of on-demand medication use and alginate formulation therapy against traditional gradual dose reduction approaches.

02 Primary Care Innovation

Research examining optimal medication management strategies in the primary care setting, particularly focusing on patients with heartburn and reflux symptoms without clear long-term treatment indications.

  • Medication Optimization
  • Patient-Centered Care
  • Chronic Disease Management

Evaluating patient outcomes and treatment success rates across different therapeutic approaches in primary care settings.

03 Therapeutic Alternatives

Investigation into sustainable treatment options for managing gastrointestinal disorders, comparing conventional medication tapering with newer therapeutic strategies.

  • Medication Reduction Strategies
  • Alternative Therapies
  • Long-term Health Outcomes

Assessing the comparative effectiveness of different treatment approaches for chronic digestive conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.